Scalper1 News
Specialty drugmaker Horizon Pharma (HZNP) jumped to a new high in early trading Monday after it issued strong preliminary Q2 sales and raised its full-year guidance. Horizon said sales in the quarter were about $170 million to $172 million, roughly a 160% increase over the year-earlier quarter and more than $40 million above analysts’ consensus, according to Thomson Reuters. It didn’t release any earnings numbers, but said Q2 EBITDA margin should Scalper1 News
Scalper1 News